Abstract
According to a report from the World Health Organization, the mortality and severity rates among patients with cancer infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are significantly higher than those of individuals infected with SARS-CoV-2 without complications. Common and cancer-specific risk factors may be involved in the mortality and severity rates of coronavirus disease 2019 (COVID-19). Various factors have been determined to contribute to the aggravation of COVID-19 in patients with cancer. However, on the basis of current research, the factors involved in the aggravation of COVID-19 in patients with cancer have not been fully investigated. In the general course of treatment for patients with cancer, the detection of the formation of metastases in other organs is common. Therefore, the present study investigates the association between lung metastatic lesion formation and SARS-CoV-2 infectivity. On the basis of the results obtained, in the pulmonary micrometastatic niche of patients with ovarian cancer, alveolar epithelial stem-like cells adjacent to the ovarian cancer were observed. Moreover, it was revealed that angiotensin-converting enzyme 2, a host-side receptor for SARS-CoV-2, was expressed in alveolar epithelial stem-like cells adjacent to the ovarian cancer in the pulmonary micrometastatic niche. Furthermore, it was also observed that the SARS-CoV-2 spike glycoprotein receptor-binding domain binds to alveolar epithelial stem-like cells. In other words, it was suggested that patients with cancer and pulmonary micrometastases may be more susceptible to SARS-CoV-2. The prevention of de novo niche formation in metastatic disease may be a new strategy for the clinical treatment of COVID-19 for patients with cancer.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This research study (Research number: UMIN000038789)
Funding Statement
This clinical research was performed with the support of the following research funding: Japan Society for the Promotion of Science for TH (grant No. 19K09840), START-program Japan Science and Technology Agency (JST) for TH (grant No. STSC20001), and National Hospital Organization Multicenter clinical study for TH (grant No. 2019- Cancer in general-02).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research study (Research number: UMIN000038789) was reviewed and approved by the Central Ethics Review Board of the National Hospital Organization Headquarters in Japan (Tokyo Japan). The authors attended a 2020 educational lecture on medical ethics supervised by the Japanese government. The completion numbers of the authors are AP0000151756 AP0000151757 AP0000151769 AP000351128. This research is clinical research (Research number: UMIN000038789), therefore consent to participate is required, therefore we have received a written consent from the subjects who participated in the clinical research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The materials and methods used in this study are listed in the supplementary material.
